These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

215 related items for PubMed ID: 1347220

  • 1. Neurochemical markers in the cerebrospinal fluid of patients with Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis and normal controls.
    Hartikainen P, Reinikainen KJ, Soininen H, Sirviö J, Soikkeli R, Riekkinen PJ.
    J Neural Transm Park Dis Dement Sect; 1992; 4(1):53-68. PubMed ID: 1347220
    [Abstract] [Full Text] [Related]

  • 2. Cerebrospinal fluid levels of angiotensin-converting enzyme, acetylcholinesterase, and dopamine metabolites in dementia associated with Alzheimer's disease and Parkinson's disease: a correlative study.
    Zubenko GS, Marquis JK, Volicer L, Direnfeld LK, Langlais PJ, Nixon RA.
    Biol Psychiatry; 1986 Dec; 21(14):1365-81. PubMed ID: 3024746
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study.
    Mollenhauer B, Locascio JJ, Schulz-Schaeffer W, Sixel-Döring F, Trenkwalder C, Schlossmacher MG.
    Lancet Neurol; 2011 Mar; 10(3):230-40. PubMed ID: 21317042
    [Abstract] [Full Text] [Related]

  • 13. CSF neurotransmitter markers in Alzheimer's disease.
    Beal MF, Growdon JH.
    Prog Neuropsychopharmacol Biol Psychiatry; 1986 Mar; 10(3-5):259-70. PubMed ID: 2879317
    [Abstract] [Full Text] [Related]

  • 14. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
    Parnetti L, Eusebi P, Lleó A.
    Front Neurol Neurosci; 2016 Mar; 39():117-23. PubMed ID: 27463974
    [Abstract] [Full Text] [Related]

  • 15. Intact protein analysis of ubiquitin in cerebrospinal fluid by multiple reaction monitoring reveals differences in Alzheimer's disease and frontotemporal lobar degeneration.
    Oeckl P, Steinacker P, von Arnim CA, Straub S, Nagl M, Feneberg E, Weishaupt JH, Ludolph AC, Otto M.
    J Proteome Res; 2014 Nov 07; 13(11):4518-25. PubMed ID: 25091646
    [Abstract] [Full Text] [Related]

  • 16. Parkinson's disease and dementia: clinical and neurochemical correlations.
    Strittmatter MM, Cramer H.
    Neuroreport; 1992 May 07; 3(5):413-6. PubMed ID: 1378766
    [Abstract] [Full Text] [Related]

  • 17. The Inflammatory Marker YKL-40 Is Elevated in Cerebrospinal Fluid from Patients with Alzheimer's but Not Parkinson's Disease or Dementia with Lewy Bodies.
    Wennström M, Surova Y, Hall S, Nilsson C, Minthon L, Hansson O, Nielsen HM.
    PLoS One; 2015 May 07; 10(8):e0135458. PubMed ID: 26270969
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Neurochemical differences in the CSF between Binswanger's and Alzheimer's disease.
    Strittmatter M, Hamann GF, Grauer MT, Cramer H, Schimrigk K.
    Dement Geriatr Cogn Disord; 1997 May 07; 8(1):34-42. PubMed ID: 8997550
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.